Off-target immune cell toxicity caused by AG-012986, a pan-CDK inhibitor, is associated with inhibition of p38 MAPK phosphorylation

Journal of Biochemical and Molecular Toxicology

Volumn 26, Issue 3, 2012, Pages 101-108

  Lee, Dong U ^a   Jessen, Bart ^a  

^a PFIZER INC   (United States)

Author keywords

Cancer therapy; Cyclin Dependent kinase; Immunotoxicity; Small molecule; T cell

Indexed keywords

AG 012986; CASPASE; CASPASE 3; CASPASE 7; CYCLIN DEPENDENT KINASE INHIBITOR; INTERLEUKIN 2; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN P17; PROTEIN P19; STAUROSPORINE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOCYTOTOXICITY; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE;

APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; CYTOTOXINS; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-2; LEUKOCYTES, MONONUCLEAR; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; STAUROSPORINE; THIAZOLES;

EID: 84858745782     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.20415     Document Type: Article

References (31)

1. Benson C, Kaye S, Workman P, Garrett M, Walton M, de Bono J. Clinical anticancer drug development: targeting the cyclin-dependent kinases. Br J Cancer 2005; 92(1): 7-12.
2. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009; 9(3): 153-166.
3. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24(11): 1770-1783.
4. Molineux G. Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 2003; 14(4): 259-264.
5. Zamboni WC, D'Argenio DZ, Stewart CF, MacVittie T, Delauter BJ, Farese AM, Potter DM, Kubat NM, Tubergen D, Egorin MJ. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clin Cancer Res 2001; 7(8): 2301-2308.
6. Zhang C, Lundgren K, Yan Z, Arango ME, Price S, Huber A, Higgins J, Troche G, Skaptason J, Koudriakova T, Nonomiya J, Yang M, O'Connor P, Bender S, Los G, Lewis C, Jessen B. Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy. Mol Cancer Ther 2008; 7(4): 818-828.
7. Jessen BA, Lee L, Koudriakova T, Haines M, Lundgren K, Price S, Nonomiya J, Lewis C, Stevens GJ. Peripheral white blood cell toxicity induced by broad-spectrum cyclin-dependent kinase inhibitors. J Appl Toxicol 2007; 27(2): 133-142.
8. Giordano M, Danova M, Pellicciari C, Wilson GD, Mazzini G, Conti AM, Franchini G, Riccardi A, Romanini MG. Proliferating cell nuclear antigen (PCNA)/cyclin expression during the cell cycle in normal and leukemic cells. Leuk Res 1991; 15(11): 965-974.
9. von Schwedler U, Kornbluth RS, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994; 91(15): 6992-6996.
10. Illanes O, Anderson S, Niesman M, Zwick L, Jessen BA. Retinal and peripheral nerve toxicity induced by the administration of a pan-cyclin dependent kinase (cdk) inhibitor in mice. Toxicol Pathol 2006; 34(3): 243-248.
11. Ramiro Ibanez F, Trajkovic D, Jessen B. Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor. Toxicol Pathol 2005; 33(7): 784-791.
12. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T, Yu VL, and Miller DK. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995; 376(6535): 37-43.
13. Ceccatelli S, Tamm C, Sleeper E, Orrenius S. Neural stem cells and cell death. Toxicol Lett 2004; 149(1-3): 59-66.
14. Waldmann T, Tagaya Y, Bamford R. Interleukin-2, interleukin-15, and their receptors. Int Rev Immunol 1998; 16(3-4): 205-226.
15. Wu CC, Hsu SC, Shih HM, Lai MZ. Nuclear factor of activated T cells c is a target of p38 mitogen-activated protein kinase in T cells. Mol Cell Biol 2003; 23(18): 6442-6454.
16. Remy G, Risco AM, Inesta-Vaquera FA, Gonzalez-Teran B, Sabio G, Davis RJ, Cuenda A. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 2010; 22(4): 660-667.
17. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005; 15(1): 11-18.
18. Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003; 546(1): 37-44.
19. Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 2003; 98(2): 129-142.
20. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. Embo J 1999; 18(18): 4969-4980.
21. Huang S, Jiang Y, Li Z, Nishida E, Mathias P, Lin S, Ulevitch RJ, Nemerow GR, Han J. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997; 6(6): 739-749.
22. Juo P, Kuo CJ, Reynolds SE, Konz RF, Raingeaud J, Davis RJ, Biemann HP, Blenis J. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases. Mol Cell Biol 1997; 17(1): 24-35.
23. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270(5240): 1326-1331.
24. Enslen H, Raingeaud J, Davis RJ. Selective activation of p38 mitogen-activated protein (MAP) kinase isoforms by the MAP kinase kinases MKK3 and MKK6. J Biol Chem 1998; 273(3): 1741-1748.
25. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997; 275(5296): 90-94.
26. Tanaka N, Kamanaka M, Enslen H, Dong C, Wysk M, Davis RJ, Flavell RA. Differential involvement of p38 mitogen-activated protein kinase kinases MKK3 and MKK6 in T-cell apoptosis. EMBO Rep 2002; 3(8): 785-791.
27. Oelgeschlager T. Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J Cell Physiol 2002; 190(2): 160-169.
28. Gao N, Kramer L, Rahmani M, Dent P, Grant S. The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1, 3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanism. Mol Pharmacol 2006; 70(2): 645-655.
29. MacCallum DE, Melville J, Frame S, Watt K, Anderson S, Gianella Borradori A, Lane DP, Green SR. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005; 65(12): 5399-5407.
30. Le Tourneau C, Faivre S, Laurence V, Delbaldo C, Vera K, Girre V, Chiao J, Armour S, Frame S, Green SR, Gianella Borradori A, Diéras V, Raymond E. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies. Eur J Cancer 2010; 46(18): 3243-3250.
31. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, Isham CR, Piens J, Rubin SL, Rubin J, Kaufmann SH, Atherton PJ, Sloan JA, Daiss MK, Adjei AA, Erlichman C. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005; 11(16): 5935-5941.